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ABSTRACT
Patients with type 2 diabetes (T2DM) have a signiﬁcantly higher risk of developing cardiovascular disease
(CVD)—namely myocardial infarction, heart failure, and stroke. Despite clear advances in the prevention
and treatment of CVD, the impact of T2DM on CVD outcome remains high and continues to escalate.
Available evidence indicates that the risk of macrovascular complications increases with the severity of
hyperglycemia, thus suggesting that the relation between metabolic disturbances and vascular damage is
approximately linear. Although current antidiabetic drugs are highly effective for the management of
hyperglycemia, most T2DM patients remain exposed to a substantial and concrete risk of CVD. Over the
last decade many glucose-lowering agents have been tested for their safety and efﬁcacy in T2DM with
CVD. Noteworthy, most of these studies failed to show a signiﬁcant beneﬁt in terms of CV morbidity and
mortality, despite intensive glycemic control. The recent trials Empagliﬂozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus PatientseRemoving Excess Glucose (EMPA-REG OUTCOME);
Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2
Diabetes (SUSTAIN-6); Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome
Results (LEADER); and Insulin Resistance Intervention After Stroke (IRIS) have shed some light on this
important clinical issue, thus showing a convincing effect of empagliﬂozin, liraglutide, and pioglitazone on
CVD outcomes. Here we provide a critical and updated overview of the main glucose-lowering agents and
their risk/beneﬁt ratio for the prevention of CVD in patients with T2DM.
 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2017) 130, S18-S29
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GLUCOSE-LOWERING STRATEGIES AND
CARDIOVASCULAR DISEASE
Epidemiologic studies have outlined a strong association
between type 2 diabetes mellitus (T2DM) and cardiovas-
cular disease (CVD).1,2 It is well established that patients
with T2DM are exposed to a signiﬁcantly higher risk to
develop myocardial infarction (MI) and stroke than matched
subjects without T2DM.2 Diabetic patients hospitalized for
unstable angina or non-Q-wave MI display a signiﬁcantly
higher 2-year morbidity and mortality as compared with
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nondiabetic subjects.3 In the seminal study by Haffner et al,4
the 7-year risk of MI was as high in diabetic patients without
prior MI as it was in nondiabetic patients with prior MI, thus
establishing diabetes as a “CV disease risk equivalent.” The
increased prevalence of CVD in the setting of T2DM can be
largely attributed to the heavy atherosclerotic burden and
adverse plaque phenotype, as well as the inability to
compensate for these alterations.5,6
Despite clear advances in the prevention and treatment of
CVD, the impact of T2DM on CVD outcome remains sig-
niﬁcant and continues to escalate as the obesity epidemic
takes its toll.7 Even though the CVD burden has been
reduced over the last decade, this is only partially true in the
diabetic patient. Data accumulated over the last 10 years
strongly suggest that the risk of macrovascular complica-
tions increases with the severity of abnormality of blood
glucose, indicating that the relation between metabolic dis-
turbances and vascular damage is approximately linear.8,9 In
the large, prospective Norfolk study, the relationship
between glycated hemoglobin (HbA1c), CVD, and total
mortality was indeed linear, even among patients without
T2DM; of note, 72% of the events occurred in persons with
HbA1c concentrations between 5% and 6.9%.
10 In other
words, CVD may already be detectable in patients with
HbA1c values below the diagnostic threshold for diabetes,
whereas in patients with overt T2DM the relative risk of
CVD has been shown to increase by approximately 16% for
every percentage point increase in HbA1c.
10
Given this background, one can certainly postulate
that—similar to hypertension and hypercholesterolemia—
approaches aiming at reducing the hyperglycemic burden
should result in a clear-cut reduction of vascular events in the
diabetic population. However, the relation between glucose-
lowering approaches and CVD is much more complex than is
the case with other cardiovascular (CV) risk factors. Indeed,
the success of glucose-lowering strategies in terms of CV
outcome cannot be easily predicted from changes in surro-
gate endpoints (such as plasma glucose levels or HbA1c).
6
Although HbA1c is a reliable marker of glycemic control, it
may explain less than 25% of the risk of developing diabetic
microvascular complications.11 This may be partially
explained by the notion that HbA1c does not correlate with
glycemic variability when adjusted for mean blood glucose,
and tailoring glucose-lowering strategies only on the level of
HbA1c may leave diabetic patients exposed to a substantial
burden of glycemic peaks and nadirs.12 Despite the
increasing number of individuals affected by T2DM, few
deﬁnitive CV outcome trials of licensed therapies have been
performed.13-15 In the present review we critically discuss the
effects of different glucose-lowering medications on CVD
outcomes (Table 1) in patients with T2DM.
METFORMIN
Metformin—a biguanide that reduces hepatic glucose
production while improving insulin sensitivity—is still
considered the ﬁrst-line drug for the treatment of T2DM
patients.16 This is mostly due to the fact that metformin is
overall well tolerated, effectively lowers HbA1c levels by
1% to 2%, has a favorable impact on body weight, does not
increase the risk of hypoglycemia when given in mono-
therapy, and last but not least, is highly cost-effective.16 Of
note, metformin is one of the few drugs showing a signiﬁ-
cant reduction of macrovascular events and diabetes-related
mortality. Cardiovascular beneﬁts of metformin mostly
derive from the UK Prospective Diabetes Study (UKPDS)
trial, the results of which were published in 1998.17 In this
trial 3867 patients with newly diagnosed T2DM were ran-
domized to intensive treatment with sulfonylureas or with
insulin, versus conventional therapy.17 A subgroup of
UKPDS patients who were overweight (>120% ideal body
weight) were randomized either to intensive therapy with
metformin (n ¼ 342) or conventional dietary measures
(n ¼ 411).17 In this group of patients, treatment with
metformin was associated with a 32% reduction of any
diabetes-related endpoint (P ¼ .002), 42% reduction in
diabetes-related death (P ¼ .017), and 36% reduction in
mortality (P ¼ .011). Most interestingly from a CV
perspective, patients receiving metformin displayed a 39%
reduction in the risk of nonfatal MI (P ¼ .01).17 Despite the
small number of patients enrolled, the protective effects of
metformin were still observed in the 10-year posttrial
monitoring of patients who survived to the end of the
UKPDS trial.18 Although HbA1c levels were no longer
different between intensive and conventional arms,
metformin-related risk reductions persisted for any diabetes-
related endpoint, MI (33%, P ¼ .005), and mortality (27%,
P ¼ .002).18 Although UKPDS provides some evidence—
albeit with limited statistical power compared with other CV
outcome trials—that metformin may represent a car-
dioprotective agent, not many randomized trials have been
performed to conﬁrm the CV beneﬁts of the drug.19 After
the publication of the UKPDS, only 1 randomized, placebo-
controlled trial was performed.20 In this relatively small
trial, 390 patients treated with insulin were randomized to
either metformin or placebo. The primary endpoint was an
aggregate of microvascular and macrovascular morbidity
and mortality, whereas the secondary endpoint was deﬁned
by microvascular and macrovascular morbidity and mor-
tality, as separate aggregate scores. After 4.3 years, met-
formin was not associated with an improvement in the
primary endpoint (hazard ratio [HR] 0.92, P ¼ .33), but
there was a reduction in the secondary endpoint of macro-
vascular events (HR 0.61, P ¼ .02). Moreover, metformin
improved body weight and glycemic control and reduced
the requirement of insulin.20 These overall positive ﬁndings
prompted the investigators to conclude that metformin
treatment should be continued after the introduction of in-
sulin in any patient with T2DM, unless contraindicated.
The remaining evidence, and perhaps the largest body of
data, comes from observational studies showing that met-
formin use, either as monotherapy or in combination with
another oral agent, has been associated with reduced CV
events, CV deaths, and total mortality.21-24 Despite the fact
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that these cohort studies all demonstrated CV beneﬁts of
metformin, they were ﬂawed by important biases arising
from the lack of group matching for all variables that could
affect the outcome. Importantly, 2 recent meta-analyses of
randomized, controlled trials evaluating the effectiveness of
metformin in T2DM patients failed to show its ability to
modify clinically relevant outcomes.25 A more careful
reading of the UKPDS results shows a higher death rate in
patients given metformin plus sulfonylurea as compared
with those given sulfonylurea alone (HR 1.60; 95% conﬁ-
dence interval [CI], 1.02-2.52). Although the UKPDS
investigators attributed this result to the play of chance
(likely due to the small sample size), there remain concerns
about the safety of metformin in this setting. Indeed, the
meta-analyses of Boussageon et al25 and Lamanna et al26
conﬁrmed an increase of CV risk when metformin was
added to sulfonylureas. Further randomized studies able to
reproduce the ﬁndings of the UKPDS study are needed to
Table 1 Properties and Cardiovascular Effects of Noninsulin Glucose-Lowering Drugs for the Treatment of Type 2 Diabetes
Drug Class CV Effects Clinical Use in Patients with CVD
Biguanides  Few randomized, but many observational studies
available
 Reduces risk of MI by 39%, diabetes-related endpoint
by 32%, diabetes-related death by 42%, mortality by
36% (UKPDS)
 Safety concerns on the association with sulfonylureas
 First choice in T2DM patients with and without
atherosclerotic vascular disease
 Precautions should be taken in patients with ACS, HF,
CKD (stages IV and V)
 Not indicated in the presence of acidosis or
dehydration
Sulfonylureas  Several observational studies available
 Reduction of microvascular complications (UKPDS)
 Increased CV mortality (UGDP trial)
 Impairment of ischemic preconditioning (?)
 Combination therapy in T2DM patients with and
without CVD (if HbA1c target not achieved afterw3 mo
of monotherapy with metformin)
 Precautions should be taken in patients with multiple
comorbidities, ACS, HF, and advanced CKD (stages IV
and V)
Thiazolidinediones  Reduce risk of MI and stroke (PROActive and IRIS trials
with pioglitazone)
 Improve diabetic dyslipidemia
 Increase HF hospitalization
 Combination therapy in T2DM patients with
and without CVD and/or CKD (up to stage V, eGFR
<15 mL/min/1.73 m2)
 Precautions should be taken in patients with ACS
 Contraindicated in patients with or at risk of HF
Glucagon-like
peptide-1 receptor
agonists
 Signiﬁcant reduction of composite CV endpoints in
LEADER and SUSTAIN-6 trials
 No signiﬁcant effects on CV mortality, nonfatal MI,
and hospitalization for HF with liraglutide and
semaglutide
 Reduced risk of nonfatal stroke with semaglutide
 Combination therapy in T2DM patients with and
without CVD (including HF and ACS)
 Limited data in patients with advanced CKD (stages IV
and V)
 Exenatide is eliminated by renal mechanisms and
should not be given in patients with severe ESRD
 Liraglutide is not eliminated by renal or hepatic
mechanisms, but it should be used with caution since
there are only limited data in patients with renal or
hepatic impairment
Dipeptidyl
peptidase-4
inhibitors
 Well tolerated
 No reduction of CV endpoints (SAVOR-TIMI 53,
EXAMINE, TECOS)
 Increased risk of HF with saxagliptin and alogliptin (?)
 Combination therapy in T2DM patients with and
without CVD
 Although sitagliptin seems to be safe, the use of
alogliptin and saxagliptin in patients with pre-existing
HF is still debated
 Indicated in patients with CKD (any stage)
Sodium glucose
cotransporter 2
inhibitors
 In the EMPA-REG OUTCOME trial, empagliﬂozin
reduced CV death, HF hospitalization, and total
mortality by 38%, 35%, and 32%, respectively
 No direct effect on the rates of MI or stroke with
empagliﬂozin
 Reduction of systolic and diastolic BP
 Combination therapy in T2DM patients with and
without CVD (paucity of data on SGLT2 in primary
prevention)
 Evidence of beneﬁt in patients with HF
 No evidence of beneﬁt in ACS
ACS ¼ acute coronary syndrome; BP ¼ blood pressure; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular disease; eGFR ¼ estimated glomerular
ﬁltration rate; EMPA-REG OUTCOME ¼ Empagliﬂozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientseRemoving Excess Glucose;
ESRD ¼ end-stage renal disease; EXAMINE ¼ Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; HF ¼ heart failure;
IRIS ¼ Insulin Resistance Intervention After Stroke; LEADER ¼ Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results;
MACE ¼ major adverse cardiovascular events; MI ¼ myocardial infarction; PROActive ¼ Prospective Pioglitazone Clinical Trial in Macrovascular Events;
SAVOR-TIMI 53¼ Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellituseThrombolysis in Myocardial Infarction; SGLT2¼
sodium glucose cotransporter 2; SUSTAIN-6 ¼ Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2
Diabetes; T2DM ¼ type 2 diabetes mellitus; TECOS ¼ Trial Evaluating Cardiovascular Outcomes with Sitagliptin; UGDP ¼ University Group Diabetes Program;
UKPDS ¼ UK Prospective Diabetes Study.
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increase conﬁdence of cardiologists regarding the clear-cut
cardioprotective effects of metformin.
SULFONYLUREAS
Sulfonylureas stimulate insulin secretion from pancreatic
b-cells by binding to the sulfonylurea receptor 1, which is
part of the Kir6.2 adenosine triphosphateesensitive potas-
sium channel. As monotherapy, sulfonylureas are effective
glucose-lowering drugs, leading to reductions in fasting
plasma glucose by 36-72 mg/dL and HbA1c by 1%-2%.
27
However, they are associated with a signiﬁcant risk of
moderate hypoglycemia, reported in 20%-40%, and severe
hypoglycemia—requiring third-party assistance—in 1%-7%
of patients, depending on the population, the deﬁnition of
hypoglycemia, and the type and pharmacokinetics of the
sulfonylurea.27 Furthermore, there are concerns about the
CV safety of sulfonylureas. In 1970 the University Group
Diabetes Program (UGDP) trial reported an increased risk of
CV death associated with the use of tolbutamide compared
with placebo or insulin.28,29 Because the Kir6.2 adenosine
triphosphateesensitive potassium channel is also expressed
in smooth muscle cells and cardiomyocytes, several authors
have postulated that the increased CV mortality reported by
UGDP could be the result of an impaired vasodilatory
response during acute myocardial ischemia. The sulfonyl-
urea glimepiride was found to impair ischemic pre-
conditioning in T2DM patients with coronary artery disease,
as compared with insulin.30 However, in contrast to glime-
piride, tolbutamide has only a low afﬁnity for cardiac sul-
fonylurea receptors, and interference with ischemic
preconditioning seems unlikely to account for the excess
mortality reported by the UGDP.28 Moreover, subsequent
studies failed to establish a deﬁnite link between sulfonyl-
urea treatment before acute MI and in-hospital mortality.
After the UGDP concerns, several randomized trials with
sulfonylureas have been performed. The A Diabetes
Outcome Prevention Trial (ADOPT), which compared
metformin, rosiglitazone, and glyburide therapy with respect
to glycemic control, did not report any difference among the
4 treatment groups as far as CV outcomes were concerned.31
However, these ﬁndings should be interpreted with caution
because the trial was not designed to test the CV safety of
glyburide. In the UKPDS; Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR Controlled Evaluation
(ADVANCE); and Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trials, in which sulfonylureas were
highly represented in the intensive glucose-lowering arms,
no increased CV risk was reported by the in-
vestigators.13,14,32,33 In contrast, a number of observational
studies support the notion that sulfonylureas may increase
CV risk, especially when compared with metformin ther-
apy.34,35 The ongoing Cardiovascular Outcome Trial of
Linagliptin Versus Glimepiride in Type 2 Diabetes
(CAROLINA) trial, which compares linagliptin with gli-
mepiride in T2DM patients, might help to clarify and deﬁne
the CV safety of these drugs.36
THIAZOLIDINEDIONES
The glucose-lowering effect of thiazolidinediones is due to
their ability to activate the peroxisome proliferatoreactivated
receptor (PPAR)-g, thus fostering insulin sensitivity in
skeletal muscle, liver, and adipose tissue.37 Thiazolidine-
diones include troglitazone, pioglitazone, and rosiglitazone.
Troglitazone was withdrawn because of hepatotoxicity,
whereas safety concerns about rosiglitazone and pioglitazone
were raised owing to increased CV risk (MI and heart failure
[HF]) and risk of bladder cancer and bone fractures,
respectively.37,38 As glucose-lowering agents, thiazolidine-
diones are well tolerated and are not associated with any risk
of hypoglycemia.27 They have also been shown to be asso-
ciated with more durable glycemic control when compared
with sulfonylureas and metformin.16 An important undesir-
able effect of this class of drugs is ﬂuid retention due to renal
sodium reabsorption, reported in 4%-6% of patients
receiving thiazolidinediones.37
A number of observational studies that have compared
rosiglitazone with other oral antidiabetic medications have
shown an increased risk of mortality and HF.39,40 A
nationwide retrospective cohort study including 227,571
Medicare beneﬁciaries aged 65 years or older showed that,
when compared with prescription of pioglitazone, prescrip-
tion of rosiglitazone was associated with an increased risk of
stroke, HF, and all-cause mortality.40 The meta-analysis by
Nissen and Wolski41 showed that rosiglitazone was associ-
ated with a signiﬁcant increase in the risk of MI and with an
increase in the risk of CV death, with borderline signiﬁcance.
Several other meta-analyses conﬁrmed adverse CV effects
associated with rosiglitazone.42,43 This evidence led to the
withdrawal of rosiglitazone in Europe and restricted its use in
the United States. On the basis of such safety concerns, the
Rosiglitazone Evaluated for Cardiac Outcomes and Regula-
tion of Glycaemia in Diabetes (RECORD) trial was specif-
ically designed to test the CV safety of rosiglitazone as
compared with placebo. The study conﬁrmed an increased
risk of HF (HR 2.10; 95% CI, 1.35-3.27), whereas data on
MI risk remained not conclusive (HR 1.14; 95% CI, 0.80-
1.63).44 After the publication of the RECORD trial, the US
Food and Drug Administration lifted some of the restrictions,
stating that rosiglitazone was not associated with increased
MI risk.32
In contrast to rosiglitazone, the CV effects of pioglita-
zone seem to be more promising. The Prospective Piogli-
tazone Clinical Trial In Macrovascular Events (PROactive)
study which was designed to investigate whether pioglita-
zone reduces macrovascular morbidity and mortality in
5238 high-risk T2DM patients followed for 34.5 months,
showed that the drug was not effective in reducing the
composite primary endpoint of all-cause mortality, nonfatal
MI, stroke, and limb amputation (HR 0.90; 95% CI, 0.80-
1.02; P ¼ .095), whereas it signiﬁcantly reduced the sec-
ondary endpoint of all-cause mortality, nonfatal MI, and
stroke (0.84; 95% CI, 0.72-0.98; P ¼ .027).45 However,
pioglitazone signiﬁcantly increased hospitalization for HF
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Table 2 Recent Randomized, Controlled Trials with Noninsulin Glucose-Lowering Drugs Showing Improvement of Cardiovascular Outcomes
Variable IRIS46 LEADER47 SUSTAIN-648 EMPA-REG OUTCOME49
No. of patients 3876 9340 3297 7020
Population Patients with recent history of
ischemic stroke or TIA, with
insulin resistance but without
T2DM
T2DM patients with CVD or
high CV risk
T2DM patients with CVD or
high CV risk
T2DM patients with CVD
Intervention Pioglitazone vs placebo Liraglutide vs placebo Semaglutide vs placebo Empagliﬂozin vs placebo
Median follow-up (y) 4.8 3.8 2.1 3.1
Mean age (y) 63 64 64 63
Mean HbA1c (%) 5.8 8.7 8.7 8.1
Mean BMI (kg/m2) 29.9 32.5 32.8 30.5
CKD (%) NR 25 70 26
Prior HF (%) 0 14 21-24 10
Deﬁnition of primary outcome Fatal or nonfatal stroke or MI CV death, nonfatal MI, or
nonfatal stroke
CV death, nonfatal MI, or
nonfatal stroke
CV death, nonfatal MI, or
nonfatal stroke
HR for primary outcome (95% CI) 0.76 (0.62-0.93), P ¼ .007 0.87 (0.78-0.97), P < .001 for
noninferiority; P ¼ .01 for
superiority
0.74 (0.58-0.95), P < .001 for
noninferiority; P ¼ .02 for
superiority
0.86 (0.74-0.99), P ¼ .04 for
superiority
Hospitalization for HF, HR
(95% CI) unless otherwise noted
3.8% vs 3.7%, P ¼ .80 0.87 (0.73-1.05), P ¼ .14 1.11 (0.77-1.61), P ¼ .57 0.65 (0.50-0.85), P ¼ .002
CV mortality, HR (95% CI) NA 0.78 (0.66-0.93), P ¼ .007 0.98 (0.65-1.48), P ¼ .92 0.62 (0.49-0.77), P < .001
All-cause mortality, HR (95% CI) 0.93 (0.73-1.17), P ¼ .52 0.85 (0.74-0.97), P ¼ .02 1.05 (0.74-1.50), P ¼ .79 0.68 (0.57-0.82), P < .001
Comments Although pioglitazone
signiﬁcantly reduced the rate
of stroke and MI, no between-
group differences in all-cause
mortality were observed.
Pioglitazone was also
associated with a greater
frequency of weight gain,
edema, and bone fractures
requiring surgery or
hospitalization.
Survival curves for 3-point MACE
started to separate after 12-18
mo from randomization,
whereas no effects were seen
for HF-related outcomes. These
ﬁndings suggest that
liraglutide may reduce CV
events mostly via an
antiatherosclerotic
mechanism.
Decreased CV risk with
semaglutide was mostly driven
by a signiﬁcant (39%)
reduction in the rate of
nonfatal stroke and a
nonsigniﬁcant (26%) decrease
in nonfatal MI, with no
signiﬁcant difference in the
rate of CV death. The beneﬁcial
effect of semaglutide on CV
outcomes may relate to
modiﬁcation of the
progression of atherosclerosis.
Beneﬁts of empagliﬂozin were
seen already after 3 mo. This
suggests that hemodynamic
factors (ie, BP reduction,
osmotic diuresis) may be
signiﬁcantly involved.
However, utilization of
b-hydroxybutyrate instead of
fatty acids might also
contribute to improve
myocardial efﬁciency thus
preventing HF. The exact
mechanisms underlying
empagliﬂozin-related beneﬁts
remain to be elucidated.
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(6% vs 4%) but not HF-related mortality. Very recently the
Insulin Resistance Intervention After Stroke (IRIS) trial,
conducted in patients without diabetes who had insulin
resistance along with a recent history of ischemic stroke or
TIA, showed that the risk of stroke or MI was lower among
patients who received pioglitazone than among those who
received placebo (Table 2).46 However, pioglitazone did
not reduce mortality. The beneﬁcial effects of pioglitazone
were mostly driven by nonglycemic effects, given the
negligible difference in HbA1c levels between pioglitazone
and placebo. In this trial pioglitazone was also associated
with a lower risk of diabetes but with higher risks of weight
gain, edema, and fracture.46 Taken together, evidence so
far available discourages the use of thiazolidinediones
(especially rosiglitazone) as ﬁrst-choice glucose-lowering
drugs for the management of T2DM patients. More
recently, dual PPAR-ag agonists have been tested in ran-
domized clinical trials; however, these drugs failed to show
a favorable CV proﬁle, as reported in the Effect of Ale-
glitazar on Cardiovascular Outcomes After Acute Coronary
Syndrome in Patients With Type 2 Diabetes Mellitus
(AleCardio) trial.50
DIPEPTIDYL PEPTIDASE-4 INHIBITORS
Dipeptidyl peptidase-4 (DPP-4) inhibitors block the
degradation of glucagon-like peptide-1 (GLP-1), gastric
inhibitory peptide, and a variety of other peptides, including
brain natriuretic peptide.51 Therefore, these drugs raise
GLP-1/gastric inhibitory peptide levels, thus leading to
insulin secretion from b-cells and decreased secretion of
glucagon from pancreatic a-cells.32 Inhibitors of DPP-4 are
effective in reducing HbA1c, do not lead to hypoglycemia,
and are not associated with weight gain.16 Several meta-
analyses of retrospective studies have shown that DPP-4
inhibitors (individually and as a class) are associated with
reductions in CV events.52 However, the studies examined
were not speciﬁcally designed to appraise the effect of
DPP-4 inhibitors on CVD.32 Three randomized trials—
Saxagliptin Assessment of Vascular Outcomes Recorded in
Patients with Diabetes MellituseThrombolysis in
Myocardial Infarction (SAVOR-TIMI 53); Examination of
Cardiovascular Outcomes with Alogliptin versus Standard
of Care (EXAMINE); and Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS)—were conducted over
the last few years to systematically investigate the CV
safety and efﬁcacy of DPP-4 inhibitors in patients with
T2DM (Table 3).53-56 In the SAVOR-TIMI 53 trial, which
randomized 16,492 high-risk T2DM patients to receive
saxagliptin or placebo, more patients in the saxagliptin
group than in the placebo group were hospitalized for HF
(3.5% vs. 2.8%; HR 1.27; 95% CI, 1.07-1.51; P ¼ .007).53
However, these ﬁndings were not paralleled by a
concomitant increase in HF-related deaths in patients taking
saxagliptin (44 and 40 cases in saxagliptin and placebo,
respectively). Subjects at greatest risk of HF hospitalization
had previous HF, an estimated glomerular ﬁltration rateT
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60 mL/min/1.73 m2, or elevated baseline levels of N-
terminal pro B-type natriuretic peptide. By contrast in the
EXAMINE trial, which randomized 5380 T2DM patients
with an acute coronary syndrome to receive alogliptin or
placebo, the incidence of HF was comparable among the
treatment arms (3.1% and 2.9%, respectively).54 However,
post hoc analyses showed that alogliptin increased HF
incidence in patients who had signs of HF at the time of
randomization (HR 1.76; 95% CI, 1.07-2.90).57 Hence, data
from SAVOR-TIMI 53 and EXAMINE conﬁrmed that
Table 3 Design and Outcomes of SAVOR-TIMI 53, EXAMINE, and TECOS Trials
Variable SAVOR-TIMI 5353 EXAMINE54 TECOS55
No. of patients 16,492 5380 14,671
Population T2DM patients with CVD or high
CV risk
T2DM with an acute MI or UA
requiring hospitalization
within the previous 15-90 d
T2DM patients with CVD or high
CV risk
Intervention Saxagliptin vs placebo Alogliptin vs placebo Sitagliptin vs placebo
Mean age (y) 65 61 65
Diabetes duration (y) 10 7 11.6
Established CVD (%) 78 100 74
Mean HbA1c (%) 8  1.4 8  1.1 7.2  0.5
Mean BMI (kg/m2) 31 28.7 30.2
Prior HF (%) 12.8 28 18
Median follow-up (y) 2.1 1.5 3.0
Hypoglycemia
Intervention 15.3 6.7 2.0*
Placebo 13.4 6.5 1.7*
Deﬁnition of primary outcome CV death, nonfatal MI, nonfatal
ischemic stroke
CV death, nonfatal MI, nonfatal
stroke
CV death, nonfatal MI, nonfatal
stroke, or UA hospitalization
HR for primary outcome (95% CI) 1.00 (0.89-1.12) 0.96 (1.16) 0.98 (0.88-1.09)
Deﬁnition of secondary
outcome
CV death, MI, stroke,
hospitalization for UA, HF, or
coronary revascularization
Primary outcome þ urgent
revascularization due to UA
within 24 hours after
hospital admission
CV death, nonfatal MI, or
nonfatal stroke
HR for secondary outcome
(95% CI)
1.02 (0.94-1.11) 0.95 (1.14) 0.99 (0.84-1.11)
Hospitalization for HF, HR
(95% CI)
1.27 (1.07-1.51) 1.19 (0.89-1.59) 1.00 (0.83-1.20)
CV mortality, HR (95% CI) 1.03 (0.87-1.22) 0.85 (0.66-1.10) 1.02 (0.90-1.15)
All-cause mortality, HR (95% CI) 1.11 (0.96-1.27) 0.88 (0.71-1.09) 1.01 (0.90-1.14)
Comments Subjects at greatest risk of HF
hospitalization had previous
HF, an eGFR 60 mL/min/
1.73 m2, or elevated baseline
levels of NT-proBNP
Post hoc analyses showed that
alogliptin increased HF
incidence in patients who
had signs of HF at the time of
randomization (HR 1.76;
95% CI, 1.07-2.90)
A recent post hoc analysis
conﬁrmed that sitagliptin
does not increase HF
hospitalization even after
adjustment for pre-existing
HF
Adverse events The rate of any hypoglycemic
event (minor and major) was
signiﬁcantly increased with
saxagliptin as compared with
placebo (15.3% vs 13.4%,
P < .001)
Incidences of hypoglycemia,
cancer, pancreatitis, and
initiation of dialysis were
similar with alogliptin and
placebo
There was no signiﬁcant
difference between
sitagliptin and placebo with
respect to the overall
incidence of infections,
cancer, site-reported renal
failure, or severe
hypoglycemia
BMI ¼ body mass index; CI ¼ conﬁdence interval; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular disease; eGFR ¼ estimated glomerular ﬁltration
rate; EXAMINE ¼ Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; HbA1c ¼ glycated hemoglobin; HF ¼ heart failure; HR ¼
hazard ratio; MI ¼ myocardial infarction; NT-proBNP ¼ N-terminal pro B-type natriuretic peptide; SAVOR-TIMI 53 ¼ Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with Diabetes MellituseThrombolysis in Myocardial Infarction; T2DM ¼ type 2 diabetes mellitus; TECOS ¼ Trial Evaluating
Cardiovascular Outcomes with Sitagliptin; UA ¼ unstable angina.
*These values refer to severe hypoglycemia only.
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DPP-4 inhibitors may increase HF hospitalization in pa-
tients with pre-existing HF and high brain natriuretic
peptide (BNP) levels at baseline (Table 3). A recent meta-
analysis including SAVOR-TIMI 53 and EXAMINE trials
has conﬁrmed a 25% increase in HF hospitalizations related
to DPP-4 inhibitors.58 In contrast, the TECOS trial, which
was launched to assess noninferiority as well as long-term
CV safety of adding sitagliptin to usual care in 14,671
patients with T2DM and CVD, showed similar outcome
rates for HF hospitalization in the 2 groups (HR 1.00; 95%
CI, 0.83-1.20; P ¼ .98).55 Sitagliptin did not increase HF
hospitalization even after adjustment for pre-existing HF, as
shown by McGuire et al in a very recent TECOS sub-
study.59 These encouraging data suggest that increased HF
risk is not a class effect of DPP-4 inhibitors. Further evi-
dence is needed to draw solid conclusions on the safety of
saxagliptin and alogliptin in people with T2DM and CVD.
The ongoing Cardiovascular Outcome Trial of Linagliptin
Versus Glimepiride in Type 2 Diabetes (CAROLINA) trial
has been designed to examine the effect of linagliptin on
CV outcomes with an active comparator (glimepiride)
rather than placebo.
GLP-1 RECEPTOR AGONISTS
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
have the ability to mimic endogenous GLP-1, resulting in a
glucose-dependent increase in insulin secretion and an
inhibition of glucagon secretion.60 Glucagon-like peptide-1
RAs are generally well tolerated; the most common adverse
effect is nausea, which is usually transient (4-8 weeks).16
The risk of hypoglycemia in patients receiving GLP-1
RAs is low, unless they are combined with insulin or sul-
fonylureas.27,61 Moreover, the reduction of HbA1c levels
with these drugs is long-lasting, and this is mostly due to a
durable effect on the pancreatic b-cell to enhance insulin
secretion.62
The receptor for GLP-1 is abundantly expressed in the
vascular endothelium, smooth muscle cells, and car-
diomyocytes, suggesting that these drugs may act on the
entire CV system.63 A series of experimental studies in
animal models has shown that GLP-1 RAs may improve
insulin sensitivity, left ventricular (LV) remodeling, and
cardiac contractility in models of chronic HF and MI.64 In
human subjects, GLP-1 RAs have shown a consistent and
favorable impact on several CV risk factors, such as body
weight, blood pressure, endothelial function, and low-
density lipoprotein cholesterol.65 In several small studies
conducted in patients with HF (with and without diabetes),
chronic infusion of GLP-1 signiﬁcantly improved LV
ejection fraction (LVEF), VO2 max, 6-minute walk distance,
and Minnesota Living with Heart Failure quality-of-life
score. Importantly, GLP-1-related beneﬁts were seen in
both diabetic and nondiabetic patients, and no episodes of
hypoglycemia or gastrointestinal side effects were
observed.66 Infusion with GLP-1 also signiﬁcantly increased
LVEF and infarct-zone-related wall motion in patients with
MI.67 A placebo-controlled, randomized study showed that
infusion of exenatide—started before reperfusion in
ST-elevation myocardial infarction patients undergoing
percutaneous coronary intervention—signiﬁcantly reduced
ischemia and myocardial salvage index (quantitated by
cardiac magnetic resonance imaging) after 3 months.68
Long-term randomized, controlled studies were recently
completed to examine whether GLP-1 RAs affect CV
outcome in high-risk individuals. The Evaluation of Lix-
isenatide in Acute Coronary Syndrome (ELIXA) trial
investigated the effects of lixisenatide versus placebo in
6068 diabetic patients with a recent acute coronary syn-
drome. The primary endpoint of CV death, MI, stroke, or
hospitalization for unstable angina occurred in 13.4% of
patients in the lixisenatide group and in 13.2% in the pla-
cebo group (HR 1.02; 95% CI, 0.89-1.17), thus showing
noninferiority of lixisenatide to placebo. However, the study
did not show superiority as far as CV outcome is con-
cerned.69 In the Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results (LEADER)
trial, T2DM patients at high CV risk were randomly
assigned to receive liraglutide or placebo. After a median
follow-up of 3.8 years, liraglutide signiﬁcantly reduced the
occurrence of the 3-point major adverse CV events by 13%,
CV death by 22%, and all-cause mortality by 15%, without
signiﬁcant effects on nonfatal MI, nonfatal stroke, and
hospitalization for HF (Table 2).47 Cardiovascular beneﬁts
of liraglutide were observed quite early as compared with
classic glycemic control trials in patients with T1DM and
T2DM (ie, Diabetes Control and Complications Trial
[DCCT], UKPDS), in which the reduction of CV events
took many more years to emerge.6 Moreover, the beneﬁts of
liraglutide were seen despite the fact that CV risk factors
were signiﬁcantly controlled by guideline-based medical
treatment. In LEADER, cumulative event curves for 3-point
major adverse CV events started to separate after 12-18
months from randomization, whereas no effects were seen
for HF-related outcomes. These ﬁndings suggest that lir-
aglutide may reduce CV events mostly via an antiathero-
sclerotic mechanism.70 Along the same line, the very recent
Trial to Evaluate Cardiovascular and Other Long-term
Outcomes with Semaglutide in Subjects with Type 2 Dia-
betes (SUSTAIN-6) trial showed that semaglutide signiﬁ-
cantly reduced the primary composite endpoint of CV death,
nonfatal MI, or nonfatal stroke (HR 0.74; 95% CI, 0.58-
0.95; P < .001 for noninferiority).48 These beneﬁcial effects
were mostly driven by a signiﬁcant (39%) reduction in the
rate of nonfatal stroke and a nonsigniﬁcant (26%) decrease
in nonfatal MI, with no signiﬁcant difference in the rate of
CV death. Moreover, treatment with semaglutide increased
retinopathy complications (HR 1.76; 95% CI, 1.11-2.78;
P ¼ .02).48 Further studies are needed to demonstrate the
mechanism whereby GLP-1 RAs improve CV outcomes in
T2DM. A deﬁnitive answer concerning the CV impact of
GLP-1 RAs as well as putative class effects awaits the
completion of the trials Exenatide Study of Cardiovascular
Event Lowering (EXSCEL; exenatide) and Researching CV
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Events with a Weekly Incretin in Diabetes (REWIND;
dulaglutide).
SODIUM GLUCOSE COTRANSPORTER 2
INHIBITORS
Sodium glucose cotransporter 2 (SGLT2) inhibitors are the
newest class of oral agents approved for the treatment of
T2DM. Their mechanism of action is inhibition of SGLT2, a
low-afﬁnity, high-capacity sodium-glucose cotransporter
located in the proximal tubule.71 Inhibition of SGLT2 leads
to the elimination of 60-80 g glucose per day; however, this
value is highly dependent on renal function and the hyper-
glycemic burden.72 The effect of SGLT2 inhibitors on
glucose elimination is proportional to glycemic levels, being
modest or even negligible in conditions of mild
hyperglycemia. This “self-limiting” action explains the low
risk of hypoglycemia associated with this class of drugs,
except when used in combination with insulin or sulfonyl-
ureas.32 Sodium glucose cotransporter 2 inhibitoreinduced
glycosuria promotes a mild diuresis and calorie loss, thus
leading to modest reductions in body weight.71 All SGLT2
inhibitors have also shown a signiﬁcant reduction in systolic
and diastolic blood pressure, with the greatest reductions
observed for systolic blood pressure.73 Emerging evidence
indicates that SGLT2 inhibitors have the ability to confer
cardioprotection in high-risk T2DM patients. The recent
Empagliﬂozin Cardiovascular Outcome Event Trial in Type
2 Diabetes Mellitus PatientseRemoving Excess Glucose
(EMPA-REG OUTCOME) trial was the ﬁrst study to show
unequivocal CV beneﬁts of an SGLT2 inhibitor (Table 2).49
The publication of this study has brought great enthusiasm
Figure Cumulative incidence of the primary outcome and cardiovascular death in the Empagliﬂozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus PatientseRemoving Excess Glucose (EMPA-REG OUTCOME)49 (A) and Liraglutide
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)47 (B) trials. Treatment with empagliﬂozin
in EMPA-REG OUTCOME led to an early and unusual divarication of the curves already after 3-6 months, whereas in LEADER
survival curves for 3-point major adverse cardiovascular events and cardiovascular death started to separate later, after 12-18 months
from randomization. Reproduced fromZinmanB, et al. Empagliﬂozin, cardiovascular outcomes, andmortality in type 2 diabetes.NEngl
JMed. 2015;373:2117-2128. Copyright 2015MassachusettsMedical Society. Reprinted with permission fromMassachusettsMedical
Society; and from Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
Copyright  2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
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among cardiologists and diabetologists because—for de-
cades—no randomized clinical trials in diabetes have
demonstrated such a signiﬁcant impact on CV and total
mortality. In EMPA-REG OUTCOME, 7020 T2DM pa-
tients at high CV risk were randomized to receive 10 mg or
25 mg of empagliﬂozin or placebo once daily. After a me-
dian observation time of 3.1 years, empagliﬂozin (pooled
10 mg and 25 mg doses) signiﬁcantly reduced the primary
composite outcome of CV death, nonfatal MI, or nonfatal
stroke (HR 0.86; 95% CI, 0.74-0.99; P ¼ .04 for superiority;
Figure).49 Although empagliﬂozin did not show a direct
effect on the rates of MI or stroke, death from CV causes,
hospitalization for HF, and death from any cause were
reduced by 38%, 35%, and 32%, respectively. A subgroup
analysis of the EMPA-REG OUTCOME data conﬁrmed
that empagliﬂozin reduces HF hospitalization and CV death,
with a consistent beneﬁt in patients with and without
baseline HF.74 As compared with the recent LEADER trial,
in which the effects of liraglutide were seen after 12 months,
beneﬁts of empagliﬂozin emerged much earlier, suggesting
that hemodynamic factors may be signiﬁcantly involved
(Figure, Table 2).75 This hypothesis is supported by the
effects of empagliﬂozin on blood pressure and by the fact
that risk of MI and stroke was not affected, whereas major
differences were observed for HF. The reduction in blood
pressure cannot entirely explain the rapid CV effects of
empagliﬂozin because previous trials with blood
pressureelowering drugs took much longer to show re-
ductions in CV outcomes.6 Undoubtedly, volume depletion
plays a major role in the reductions of HF hospitalizations,
and this was also demonstrated by a 4% increase in he-
matocrit. Cardiac utilization of b-hydroxybutyrate in place
of fatty acids might also contribute to transduce oxygen
consumption into work efﬁciency at the mitochondrial
level.76 Although further studies are needed to explain the
improvement of CV outcomes with empagliﬂozin, the
beneﬁts of this drug on CV outcomes is indisputable, at least
as far as HF and CV mortality are concerned. A very recent
meta-analysis including 81 trials with a total of 37,195 pa-
tients and mean follow-up of 89 weeks showed that SGLT2
inhibitors were associated with a lower risk of all-cause
mortality (odds ratio [OR] 0.72; 95% CI, 0.59-0.86; P <
.001), CV mortality (OR 0.67; 95% CI, 0.53-0.84; P ¼
.001), and HF (OR 0.67; 95% CI, 0.51-0.87; P ¼ .003), but
a similar risk of MI (OR 0.89; 95% CI, 0.74-1.09; P ¼ .29)
and stroke/transient ischemic attack (OR 1.09; 95% CI,
0.87-1.37; P ¼ .47) as compared with placebo. The reduc-
tion in all-cause mortality was noticed with empagliﬂozin
but not with other SGLT2 inhibitors.77 A potential harm was
observed with dapagliﬂozin on CV mortality (OR 2.15; 95%
CI, 0.92-5.04; P ¼ .08).77
CONCLUSIONS
The management of CVD in patients with T2DM is a fast-
growing ﬁeld. Over the last few years several trials have
proven CVD safety of different antidiabetic drugs, whereas
other studies—namely EMPA-REG OUTCOME, LEADER,
SUSTAIN-6, and IRIS—have shown a beneﬁt of empagli-
ﬂozin, liraglutide, semaglutide, and pioglitazone on CV
outcomes. Although these data are very promising, there
remain important aspects that require clariﬁcation. These
include (1) the exact mechanisms by which these drugs may
have yielded rapid CV beneﬁts as compared with other
classes of antidiabetic drugs; (2) which patients may beneﬁt
more from these drugs (ie, patients with HF, kidney disease,
etc); and (3) whether these drugs are equally effective in
T2DM patients without CVD (primary prevention). Ongoing
and future studies will help to clarify these important issues.
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